SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Sonny Liston — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSonny Liston
Date of birth1932-05-08
IdentifiersMRN HR-BX007-SYN-TD; SSN (made up) 000-07-8853
Document date1969-10-20
AuthorMalcolm Achebe-Whitford, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-month review of blood pressure and drinking. [S]

History of Present Illness

Sonny Liston returns for his four-month review. The commission physician cleared him to box after reviewing his readings, and he is back to full sparring. His home readings average 120/76 mmHg. He takes amlodipine 10 mg and valsartan 160 mg and naltrexone 50 mg each morning. He drinks about eight drinks a week, never more than three in a day, and none in the two weeks before a bout. He is sleeping well and says he feels sharper in training. He has thought about the adult reading class he was told about and wants to wait until after his next fight. No thoughts of suicide. [S]

ElementDetail
Home readingsAverage 120/76 mmHg
AUDIT7, from 16 at intake
GGT41 U/L, normal
PHQ-92; item 9 scored 0
Vaccine todayInfluenza

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations or swelling at rest
NeurologicalNegativeNo dizziness or headaches
GastrointestinalNegativeNo nausea
PsychiatricNegativeMood good; no thoughts of suicide

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route1969-06-23 to 1969-07-21completedS
Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morningOne tablet each morningOral route1969-07-21activeS
Naltrexone 50 mg oral tablet, one tablet each morningOne tablet each morningOral route1969-07-21activeS
Pseudoephedrine 30 mg oral tablet, bought over the counter as a cold tablet, two tablets up to four times a dayTwo tablets up to four times a dayOral route1969-09-05 to 1969-09-08stoppedS
Acetaminophen 500 mg oral tablet, one or two tablets every six hours as needed for aches, no more than four tablets (2 g) a day because he drinksOne or two tablets every six hours as needed; no more than four tablets a dayOral route1969-09-08 to 1969-09-15completedS
Saline nasal spray 0.65%, two sprays in each nostril as neededTwo sprays in each nostril as neededNasal route1969-09-08 to 1969-09-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1969-10-20Body height185cmS
1969-10-20Body weight97kgS
1969-10-20Body mass index (BMI) [Ratio]28.3kg/m2S
1969-10-20Systolic blood pressure122mm[Hg]S
1969-10-20Diastolic blood pressure76mm[Hg]S
1969-10-20Heart rate56/minS
1969-10-20Respiratory rate14/minS
1969-10-20Body temperature36.5CelS
1969-10-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1969-10-20Total score [AUDIT]7{score}S
1969-10-20Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma41U/L8-61 U/LNormalS
1969-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 1969-10-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/76 mmHg (average of two); pulse 56; weight 97.0 kg
CardiovascularRegular rhythm; no edema

Problems

ProblemClinical statusVerificationCodeProvenance
High blood pressure readings at a first visit (154/98 mmHg, average of two readings with a large cuff), without a diagnosis of hypertension; out-of-office confirmation neededresolvedconfirmed R03.0S — Synthetic presenting finding; resolved into the diagnosis at the consultation visit when ambulatory monitoring confirmed hypertension.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (daytime average 146/94 mmHg, nighttime 132/84 mmHg), with mild concentric left ventricular hypertrophy on echocardiography and normal kidney function and urine albuminactiveconfirmed I10S — Synthetic modern diagnosis; no hypertension is documented in his life.
Alcohol use disorder, moderate (four DSM-5-TR criteria: drinking more than intended, unsuccessful efforts to cut down, craving, and continued drinking despite its effect on his training, blood pressure and liver tests); AUDIT 16activeconfirmed F10.20S — Synthetic modern diagnosis by interview, anchored to the description of heavy drinking; not a historical diagnosis.
Personal history of physical abuse in childhood (beaten regularly by his father), with heavy field work from the age of eightactiveconfirmed Z62.810S — Synthetic coding of the documented childhood history; physical abuse only.
Does not read or write (no schooling as a child); prefers spoken explanations, pictures and demonstrationsactiveconfirmed Z55.0S — Synthetic coding of the documented literacy, recorded so that care is adapted.
Acute viral upper respiratory infection (common cold) for four days, with blood pressure raised to 158/98 mmHg by an over-the-counter pseudoephedrine cold tablet he could not read the label of; resolvedresolvedconfirmed J06.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, large cuff, average of two readings), weight and BMI, heart soundsEvery visitCompleted today122/76 mmHg; weight 97.0 kg
ExaminationOut-of-office blood pressure (ambulatory or home monitoring)At diagnosis and after each treatment changeCompleted todayHome average 120/76 mmHg
LaboratoryPotassium, creatinine and eGFRBaseline; two to four weeks after starting an ARB; then every six months on an ARBDueNext in about two months, six months after starting valsartan
LaboratoryLipids, glucose or A1c, urine albumin-to-creatinine ratio, TSHAt diagnosis, then yearly (TSH at diagnosis)Up to dateDone at intake; next at the preventive visit next year
ImagingEchocardiogramAt diagnosis for stage 2 hypertension or suspected LVH; repeat as indicatedUp to dateRepeat in about eight months
Medication safetyAntihypertensive tolerance (ankle edema, dizziness) and adherence by teach-backEach follow-up and each dose changeCompleted todayNo edema today; no dizziness; teach-back correct
ReferralFitness to compete (AHA/ACC athlete statement)At diagnosis and before returning to competitionCompleted todayCleared by the commission physician; blood pressure checked before each bout
SurveyDrinking (AUDIT-C, drinks per week, drinking days)Every follow-up during treatment; full AUDIT at about four monthsCompleted todayFull AUDIT 7, from 16; about 8 drinks a week
LaboratoryLiver tests (AST, ALT, GGT)Baseline; about two months after starting naltrexone or cutting down; then as indicatedCompleted todayGGT 41 U/L, now normal
Medication safetyNaltrexone: nausea, liver tests, and opioid-blockade wallet cardEach follow-up after startingCompleted todayWell tolerated; wallet card carried
SurveyPHQ-9Yearly with hypertension; sooner with symptomsCompleted todayPHQ-9 2, item 9 scored 0
SurveySuicide-risk review (structured questions) and safety planEvery visitCompleted todayNo thoughts of suicide; safety plan kept
Self-managementHealth literacy: teach-back, picture card, read-aloud consent, voice remindersEvery visitCompleted todayTeach-back correct; the adult reading class offered again, and he will decide after his next fight

Goal progress:

Immunizations given today: Influenza vaccine, 1969-1970 season [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (Black HR, et al.) (2015); The Healthcare Professional's Core Resource on Alcohol (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024); Adult Immunization Schedule by Age (2026)

Follow-up: Potassium and creatinine in about two months. Review in three months, sooner after any bout with a head injury. Preventive visit in ten months. Call 988 or the clinic at any time if thoughts of suicide arise. [S]